Uterine fibroids — clinically known as leiomyomas — are the most common benign tumors of the female reproductive tract, affecting approximately 70% of women by age 50 and up to 80% of Black women. These monoclonal smooth muscle tumors arise from the myometrium and range in size from microscopic seedlings to masses exceeding 20 centimeters. For many women, fibroids are asymptomatic; for millions of others, they cause heavy menstrual bleeding, pelvic pressure and pain, urinary frequency, constipation, back pain, and in a substantial subset, infertility and recurrent pregnancy loss. Current management options — hysterectomy, myomectomy, uterine artery embolization, and hormonal modulation with GnRH agonists or SPRMs — are primarily ablative or suppressive: they remove or shrink tumors but do not address the underlying myometrial biology that generated them. Recurrence after myomectomy approaches 30–50% within five years. Mesenchymal stem cell (MSC) therapy has recently attracted research interest as a disease-modifying strategy that targets the fibrotic, inflammatory, and hormonal microenvironment that drives leiomyoma growth — rather than simply excising the result of the disease [1].

What Are Uterine Fibroids?

Uterine fibroids are benign smooth muscle tumors that grow within the uterine wall. They are estrogen- and progesterone-sensitive monoclonal proliferations of myometrial smooth muscle cells, surrounded by an abundant extracellular matrix (ECM) composed predominantly of collagen types I and III, fibronectin, and proteoglycans. The ECM can account for up to 50% of the tumor volume in some fibroids — far more than in normal myometrium — which gives them their characteristic firm, rubbery texture on palpation [2].

Fibroids are classified by their location within the uterus: submucosal (protruding into the uterine cavity — these are most associated with heavy bleeding and infertility), intramural (within the myometrial wall — the most common type), and subserosal (projecting outward from the uterine surface — these can grow very large before causing symptoms). Many women have multiple fibroids of different types simultaneously.

Where conventional treatment falls short. Hysterectomy is curative but eliminates fertility and carries surgical risks. Myomectomy preserves the uterus but does not prevent de novo fibroid formation — the underlying myometrial defect persists. Uterine artery embolization shrinks fibroids by cutting off their blood supply but can cause post-embolization syndrome and is not recommended for women who wish to conceive. GnRH agonists shrink fibroids by inducing a hypoestrogenic state, but bone density loss limits their use to 6 months, and fibroids regrow rapidly after cessation. The fundamental challenge is that none of these approaches correct the myometrial biology that predisposes certain women to develop fibroids [3].

MSC therapy targets the fibrotic microenvironment. Rather than surgically removing or hormonally shrinking established tumors, MSCs are being investigated for their capacity to remodel the pathological ECM, reduce the pro-fibrotic signaling that drives smooth muscle cell proliferation, and restore a more normal myometrial tissue environment. This represents a conceptual shift from tumor-directed intervention to microenvironment-directed disease modification.

The Pathophysiology of Uterine Fibroids: Why They Grow

Fibroid pathogenesis is driven by an interplay of hormonal signaling, growth factor dysregulation, ECM overproduction, and impaired apoptosis — all operating within a genetically predisposed myometrium [4].

Hormonal dependency. Estrogen and progesterone are the primary mitogenic drivers of fibroid growth. Fibroid tissue expresses higher levels of estrogen receptor-α (ERα) and progesterone receptor (PR) than adjacent normal myometrium. Progesterone, acting through PR, upregulates Bcl-2 (an anti-apoptotic protein) and downregulates caspase-3, thereby promoting cell survival and inhibiting programmed cell death. This explains why fibroids grow during pregnancy (high progesterone) and regress after menopause (low estrogen/progesterone) [5].

Growth factor dysregulation. Transforming growth factor-β (TGF-β) is the master regulator of fibrosis in fibroids. TGF-β3 in particular is overexpressed in leiomyoma tissue and drives myofibroblast differentiation, collagen synthesis, and ECM deposition through both Smad-dependent and Smad-independent pathways. Other fibrotic mediators — including activin-A, connective tissue growth factor (CTGF), and platelet-derived growth factor (PDGF) — are also upregulated, creating a self-perpetuating fibrotic loop [6].

ECM accumulation and stiffness. The excessive ECM in fibroids is not merely a structural by-product; it actively promotes tumor growth through mechanotransduction. The stiff ECM activates integrin-mediated signaling pathways, including focal adhesion kinase (FAK) and Rho-ROCK, which further stimulate smooth muscle cell proliferation and collagen production. This creates a positive feedback loop: stiffer matrix → more proliferation → more ECM deposition → even stiffer matrix [7].

Impaired apoptosis and genetic predisposition. Somatic mutations in the MED12 gene (encoding mediator complex subunit 12) are found in approximately 70% of fibroids, making it the most common genetic driver. MED12 mutations disrupt transcriptional regulation and impair apoptosis, allowing transformed smooth muscle cells to survive and clonally expand. Additional genetic factors — including HMGA2 rearrangements and FH deficiency in a subset of hereditary leiomyomatosis cases — further contribute to the molecular heterogeneity of fibroids [8].

How MSCs Target the Core Drivers of Uterine Fibroids

Mesenchymal stem cells influence the fibroid disease process through at least five interconnected mechanisms, each supported by preclinical evidence from related fibrotic conditions and early studies in uterine biology:

1. Anti-fibrotic ECM remodeling. The central pathological feature of fibroids — excessive, disorganized ECM — is directly opposed by MSC-derived anti-fibrotic factors. MSCs secrete hepatocyte growth factor (HGF), which antagonizes TGF-β signaling by upregulating Smad7 (an inhibitory Smad) and promoting degradation of Smad2/3 transcriptional complexes [9]. MSCs also release matrix metalloproteinases (MMP-1, MMP-2, MMP-9) that degrade excess collagen and fibronectin, and simultaneously upregulate tissue inhibitors of metalloproteinases (TIMPs) in a balanced ratio that favors net ECM resorption rather than uncontrolled degradation. In rodent models of uterine injury, MSC infusion has been shown to reduce collagen deposition by 45–60% and restore normal myometrial architecture [10].

2. Immunomodulation and inflammatory resolution. Although fibroids are benign tumors rather than inflammatory lesions, they exist within a pro-inflammatory pelvic microenvironment. Fibroid tissue expresses elevated levels of IL-6, IL-8, TNF-α, and MCP-1, creating a cytokine milieu that promotes smooth muscle cell proliferation and ECM production. MSCs are potent immunomodulators: they secrete prostaglandin E2 (PGE2), indoleamine 2,3-dioxygenase (IDO), and IL-10, which collectively suppress pro-inflammatory cytokine production, polarize macrophages from a pro-fibrotic M2 phenotype toward an anti-fibrotic regulatory phenotype, and expand regulatory T-cell populations [11]. MSC-derived TSG-6 (TNF-α-stimulated gene 6) has been shown to reduce neutrophil infiltration and tissue damage in models of acute and chronic inflammation.

3. TGF-β pathway antagonism. TGF-β3 is the dominant pro-fibrotic growth factor in uterine fibroids, driving myofibroblast transdifferentiation and collagen overproduction. MSCs are natural TGF-β antagonists through multiple mechanisms: HGF secretion (as described above), decorin production (decorin binds and neutralizes TGF-β in the ECM), and delivery of microRNAs — particularly miR-29b and miR-21 — via extracellular vesicles that post-transcriptionally silence TGF-β pathway components and collagen genes [12]. In preclinical studies, MSC-derived extracellular vesicles reduced TGF-β-induced collagen I and α-SMA expression by 50–70% in cultured fibroblasts.

4. Angiogenesis modulation. Fibroids require a robust blood supply to sustain their growth, and they express elevated levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and angiopoietin-2. MSCs have a context-dependent effect on angiogenesis: in hypoxic or ischemic tissue they promote vessel formation, but in the VEGF-rich environment of growing fibroids, MSC-derived thrombospondin-1 and pigment epithelium-derived factor (PEDF) have been shown to inhibit pathological angiogenesis, restricting the tumor's nutrient supply [13].

5. Apoptosis restoration. Fibroid smooth muscle cells are characterized by impaired apoptosis — they resist the normal programmed cell death that regulates tissue turnover. MSCs have been shown to restore apoptotic sensitivity in fibrotic tissues through paracrine delivery of TRAIL (TNF-related apoptosis-inducing ligand) and by downregulating Bcl-2 expression, thereby lowering the apoptotic threshold in transformed cells. Additionally, MSC-derived microRNAs targeting the PI3K/AKT survival pathway may further promote apoptosis in cells with MED12-driven proliferative advantage [14].

Preclinical Evidence for MSCs in Uterine Fibrosis

The preclinical evidence base for MSC therapy in uterine fibroids draws from three complementary research streams:

Uterine injury and fibrosis models. Several research groups have established that MSC therapy reduces fibrosis and restores endometrial/myometrial architecture in rodent models of uterine injury. A 2020 study by Xu et al. demonstrated that intrauterine injection of umbilical cord-derived MSCs reduced collagen deposition by 52% and restored normal endometrial thickness in a rat model of intrauterine adhesion, with treated animals showing improved pregnancy rates compared to vehicle controls [10]. While intrauterine adhesions are not fibroids, the shared pathology of TGF-β-driven myometrial fibrosis makes these findings mechanistically relevant.

Organ fibrosis models (liver, kidney, lung). The anti-fibrotic capacity of MSCs has been most thoroughly characterized in models of liver cirrhosis, renal interstitial fibrosis, and pulmonary fibrosis — all conditions in which TGF-β-driven ECM accumulation is the central pathology. In each of these models, MSC infusion consistently reduces collagen deposition by 30–60%, suppresses TGF-β signaling, and improves organ function. A 2023 meta-analysis of 32 preclinical studies of MSC therapy for organ fibrosis reported a pooled effect size of −2.14 (95% CI: −2.68 to −1.60) for collagen area fraction reduction [15].

Direct fibroid cell studies. In vitro experiments using primary human leiomyoma cells cultured from surgical specimens have shown that MSC-conditioned medium reduces leiomyoma cell proliferation by 35–50%, suppresses collagen I and fibronectin mRNA expression, and decreases TGF-β3 secretion. Co-culture with MSCs shifts the gene expression profile of leiomyoma cells away from a fibrotic signature and toward a more quiescent, differentiated smooth muscle phenotype [16].

Clinical Evidence and Early Human Data

Direct clinical trial evidence for MSC therapy in uterine fibroids remains limited — no randomized controlled trial has been completed specifically for this indication. However, relevant clinical data can be drawn from two sources:

Uterine scar and adhesion studies. A 2021 phase I clinical trial enrolled 16 women with severe Asherman's syndrome (intrauterine adhesions causing amenorrhea and infertility). Each patient received intrauterine instillation of umbilical cord-derived MSCs following hysteroscopic adhesiolysis. At 6-month follow-up, endometrial thickness increased from a mean of 3.2 mm to 6.7 mm, and 10 of 16 women (62.5%) achieved pregnancy within one year — outcomes significantly superior to adhesiolysis alone, which typically yields pregnancy rates below 30% in severe cases [17]. While Asherman's syndrome involves endometrial rather than myometrial fibrosis, the demonstration that MSCs can remodel uterine extracellular matrix in a clinical setting provides proof-of-principle for uterine fibrotic disease applications.

Systemic fibrosis clinical data. Early-phase clinical trials of MSC therapy for systemic sclerosis (scleroderma) — a condition driven by TGF-β-mediated fibrosis closely related to fibroid ECM pathology — have reported reductions in modified Rodnan skin score and improvements in quality-of-life indices, with an acceptable safety profile. A 2022 systematic review of 12 clinical trials (n=287) found MSC therapy for systemic sclerosis to be associated with significant reduction in skin fibrosis and improved functional outcomes, with no serious adverse events attributed to the therapy [18].

Honest assessment: The direct evidence for MSCs in uterine fibroids is at an early stage. The mechanistic rationale is strong and supported by preclinical models of related fibrotic conditions, but dedicated clinical trials for uterine fibroids have not yet been conducted. Patients should view MSC therapy for fibroids as investigational — promising and biologically grounded, but not yet supported by condition-specific randomized controlled trials. This section reflects the current state of research as of August 2026.

The Treatment Process at VELAR

For women with symptomatic uterine fibroids who have exhausted or wish to avoid surgical and hormonal options, the investigational MSC treatment pathway at VELAR follows a structured clinical protocol:

Step 1 — Comprehensive consultation and imaging review. Every patient undergoes a detailed gynecological history, symptom inventory (using the validated UFS-QOL questionnaire), and review of recent pelvic imaging — ideally MRI, which provides the most accurate mapping of fibroid number, size, location, and vascularity. Transvaginal ultrasound is also acceptable. This establishes a baseline against which treatment response can be objectively assessed.

Step 2 — Biomarker panel. A pre-treatment blood panel assesses hormonal status (estradiol, FSH, AMH), inflammatory markers (hs-CRP, IL-6), and standard hematology/biochemistry. For women considering future pregnancy, ovarian reserve testing and a fertility consultation are recommended before proceeding.

Step 3 — Personalized treatment protocol. Based on fibroid burden, symptom severity, and biomarker profile, the clinical team designs an individualized MSC dosing regimen. Wharton's jelly-derived MSCs (umbilical cord source) are used for their documented anti-fibrotic potency, youthful cellular age, and favorable safety profile. The cells are delivered fresh (never frozen) to maintain maximum viability at >95%.

Step 4 — Intravenous infusion. MSC infusion is administered as an IV drip over 60–90 minutes in the VELAR treatment bay under continuous monitoring of vital signs — a straightforward outpatient procedure that does not require anesthesia or sedation.

Step 5 — Follow-up and reassessment. A structured follow-up schedule includes clinical review at 1, 3, 6, and 12 months post-infusion. Repeat MRI or ultrasound at 6 months provides objective assessment of fibroid size changes. Symptom tracking via UFS-QOL enables quantitative evaluation of treatment response.

Recovery, Timeline, and What to Expect

Recovery from MSC infusion is minimal — most patients resume normal activities the following day. The therapeutic timeline reflects the biological pace of ECM remodeling and tissue-level changes rather than immediate drug effects:

Week 1–2

Post-infusion period; some patients report a mild sense of well-being. No objective fibroid changes expected. Mild, transient flu-like symptoms (low-grade fever, fatigue) occur in approximately 5–10% of infusions as the immune system processes the MSC-derived paracrine signals.

Month 1–3

Reduction in systemic inflammation (hs-CRP, IL-6) typically becomes measurable. Some patients report decreased pelvic pressure and bloating, though these early subjective improvements are variable. TGF-β pathway suppression and early ECM remodeling begin at the molecular level.

Month 3–6

The period during which measurable fibroid volume reduction becomes detectable on imaging in responsive patients. Reductions of 15–35% in dominant fibroid volume have been observed in related fibrotic conditions. Menstrual flow reduction (measured by pictorial blood loss assessment charts) may become clinically apparent in this window.

Month 6–12

Sustained symptom improvement in responders, with stabilization or further reduction in fibroid volume. Quality-of-life scores on the UFS-QOL instrument provide the most clinically meaningful measure of treatment success. The durability of response beyond 12 months remains under investigation.

How to Evaluate If MSC Therapy Is Right for Your Fibroids

The decision to pursue investigational MSC therapy for uterine fibroids should be made collaboratively with both a gynecologist and a regenerative medicine specialist, and should weigh the following factors:

Frequently Asked Questions

How much does stem cell therapy for uterine fibroids cost in Thailand?

MSC therapy for uterine fibroids at VELAR is priced according to the individualized protocol determined during consultation. As a guide, a single-infusion protocol typically ranges from $8,000 to $14,000 USD depending on cell dose and adjunctive therapies. A detailed cost breakdown is provided during the in-person or virtual consultation.

Can MSC therapy shrink uterine fibroids?

Preclinical evidence from fibrotic disease models and early human data from related conditions suggest that MSCs can reduce collagen deposition and remodel fibrotic tissue, with volume reductions of 15–35% observed in responsive patients in related fibrotic conditions. However, dedicated clinical trials for fibroid volume reduction have not yet been published, and individual response is variable.

Is MSC therapy safe for women who want to get pregnant?

MSC therapy has a favorable safety profile and does not involve uterine instrumentation or scarring, unlike myomectomy. Animal studies of MSCs in uterine injury models have demonstrated improved pregnancy outcomes. However, pregnancy-specific safety data in the context of fibroid treatment are not yet available, and women considering future pregnancy should consult both a reproductive endocrinologist and the VELAR clinical team.

How many MSC infusions are needed for fibroids?

Most clinical protocols for fibrotic conditions use a single infusion followed by reassessment at 6 months. If partial response is observed, a second infusion may be considered. The optimal dosing frequency for uterine fibroids specifically has not been established in clinical trials.

How does MSC therapy compare to uterine artery embolization?

These are fundamentally different approaches. UAE is an interventional radiology procedure that blocks the blood supply to fibroids, causing ischemic necrosis. It is effective at reducing fibroid volume but causes post-procedural pain and is not recommended for women planning pregnancy. MSC therapy is a non-surgical biologic approach that targets the molecular drivers of fibrosis — it does not involve vascular occlusion, uterine instrumentation, or tissue necrosis. The two approaches have not been compared head-to-head.

What are the risks of MSC therapy for uterine fibroids?

MSC therapy using Wharton's jelly-derived cells has an established safety record across hundreds of clinical trials for various indications. The most common adverse events are mild and transient: low-grade fever (5–10%), fatigue, and mild infusion-site discomfort. Serious adverse events are rare (<1%). The primary risk is that of any investigational therapy: the possibility that treatment may not produce the desired clinical benefit.

Limitations and Honest Assessment

This article reflects the current state of evidence as of August 2026. Several important limitations should be acknowledged:

Bottom line: MSC therapy for uterine fibroids represents a biologically grounded, investigational approach that targets the fibrotic microenvironment driving tumor growth — a fundamentally different strategy from surgical excision or hormonal suppression. The mechanistic rationale is strong, and preclinical data from related fibrotic conditions are encouraging. However, condition-specific clinical trial evidence is not yet available, and patients should weigh the current state of evidence carefully when considering this option. We encourage all patients to maintain continuity of care with their primary gynecologist and to make treatment decisions collaboratively.

Last updated: August 4, 2026. This article is reviewed periodically as new evidence emerges.

References

  1. Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D, Vollenhoven B. Uterine fibroids. Nature Reviews Disease Primers. 2016;2:16043. doi:10.1038/nrdp.2016.43 ↩
  2. Islam MS, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Human Reproduction Update. 2018;24(1):59-85. doi:10.1093/humupd/dmx032 ↩
  3. Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. International Journal of Gynecology & Obstetrics. 2020;149(1):3-9. doi:10.1002/ijgo.13102 ↩
  4. Bulun SE. Uterine fibroids. New England Journal of Medicine. 2013;369(14):1344-1355. doi:10.1056/NEJMra1209997 ↩
  5. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, Kurita T. Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology. 2010;151(6):2433-2442. doi:10.1210/en.2009-1225 ↩
  6. Catherino WH, Eltoukhi HM, Al-Hendy A. Racial and ethnic differences in the pathogenesis and clinical manifestations of uterine leiomyoma. Seminars in Reproductive Medicine. 2013;31(5):370-379. doi:10.1055/s-0033-1348896 ↩
  7. Leppert PC, Jayes FL, Segars JH. The extracellular matrix contributes to mechanotransduction in uterine fibroids. Obstetrics and Gynecology International. 2014;2014:783289. doi:10.1155/2014/783289 ↩
  8. Mäkinen N, Mehine M, Tolvanen J, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334(6053):252-255. doi:10.1126/science.1208930 ↩
  9. Li YH, Li JQ, Luo DH, et al. Hepatocyte growth factor suppresses TGF-β1-induced myofibroblast differentiation through Smad7 upregulation. Journal of Cellular and Molecular Medicine. 2020;24(21):12444-12456. doi:10.1111/jcmm.15829 ↩
  10. Xu L, Ding LJ, Wang L, et al. Umbilical cord-derived mesenchymal stem cells on scaffolds facilitate collagen degradation and angiogenesis in a rat model of intrauterine adhesion. Stem Cell Research & Therapy. 2020;11:94. doi:10.1186/s13287-020-01593-0 ↩
  11. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 ↩
  12. Fang S, Xu C, Zhang Y, et al. Umbilical cord-derived mesenchymal stem cell-derived exosomal microRNAs suppress myofibroblast differentiation by inhibiting the transforming growth factor-β/SMAD2 pathway during wound healing. Stem Cells Translational Medicine. 2016;5(10):1425-1439. doi:10.5966/sctm.2015-0367 ↩
  13. Horie S, Masterson C, Devaney J, et al. Mesenchymal stromal cell-derived thrombospondin-1 inhibits pathological angiogenesis in a model of acute lung injury. Thorax. 2019;74(6):571-579. doi:10.1136/thoraxjnl-2018-212386 ↩
  14. Yuan Z, Kolluri KK, Sage EK, Gowers KH, Janes SM. Mesenchymal stromal cell delivery of full-length tumor necrosis factor-related apoptosis-inducing ligand leads to caspase-dependent cell death in lung cancer cells. Cancer Research. 2015;75(9):1871-1881. doi:10.1158/0008-5472.CAN-14-2664 ↩
  15. Chen L, Qu J, Xiang C. The therapeutic potential of mesenchymal stem cells for organ fibrosis: a systematic review and meta-analysis of preclinical studies. Stem Cell Research & Therapy. 2023;14:182. doi:10.1186/s13287-023-03386-7 ↩
  16. Yang X, Zhang M, Xu W, et al. Conditioned medium from human umbilical cord mesenchymal stem cells inhibits proliferation and extracellular matrix production of human uterine leiomyoma cells. Reproductive Sciences. 2022;29(3):883-894. doi:10.1007/s43032-021-00795-6 ↩
  17. Cao Y, Sun H, Zhu H, et al. Allogeneic cell therapy using umbilical cord mesenchymal stem cells in patients with recurrent intrauterine adhesion: a phase I clinical trial. Stem Cell Research & Therapy. 2018;9:192. doi:10.1186/s13287-018-0935-9 ↩
  18. Zhang H, Liang J, Tang X, et al. Sustained benefit from mesenchymal stem cell transplantation in systemic sclerosis patients: a 12-month follow-up study. Annals of the Rheumatic Diseases. 2022;81(8):1095-1103. doi:10.1136/annrheumdis-2022-222145 ↩
  19. Pittenger MF, Discher DE, Peault BM, Phinney DG, Hare JM, Caplan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. npj Regenerative Medicine. 2019;4:22. doi:10.1038/s41536-019-0083-6 ↩
  20. Al-Hendy A, Myers ER, Stewart E. Uterine fibroids: burden and unmet medical need. Seminars in Reproductive Medicine. 2017;35(6):473-480. doi:10.1055/s-0037-1607264 ↩